FibroBiologics Doses First CYWC628 Patients

FibroBiologics, a clinical-stage biotechnology company, announced that the first patients have been dosed in its Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). This significant milestone, which occurred during the week of June 1, 2026, marks the transition of the science from laboratory to patient care. The trial is being conducted across multiple sites in Australia, following approvals from Human Research Ethics Committees and completion of the required Therapeutics Goods Administration filing. Concurrently, FibroBiologics has advanced the manufacturing of CYWC628, with drug product from its second good manufacturing practice (GMP) run released and scheduled for shipment to Australia, and the first two batches of its third GMP run completed. Pete O Heeron, CEO, and Hamid Khoja, CSO, highlighted the importance of this step in addressing chronic wounds with a novel fibroblast-based therapy.